Compass Pathways to Announce New Clinical Data from Two Ongoing Phase 3 Trials

Core Insights - Compass Pathways plc is set to report new clinical data from two ongoing Phase 3 trials evaluating COMP360, a synthetic formulation of psilocybin for treatment-resistant depression (TRD) [1] Group 1 - The company will disclose new clinical data from Part A and Part B of trial COMP005 and Part A of trial COMP006 [1]